Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | G6PD | P11413 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7907649 | 0.91 | ALDH1A1 (0.44) | RAB9AALDH1A1KDM4EPOLBHPGD | |
| SCHEMBL1726455 | 0.81 | GRIN2D (0.46) | RAB9AALDH1A1KDM4EPOLBPKM | |
| SCHEMBL7898849 | 0.80 | KDM4E (0.51) | ALDH1A1KDM4EPOLBHPGDPKM | |
| SCHEMBL7907359 | 0.78 | HSP90AA1 (0.41) | RAB9AALDH1A1KDM4EPOLBHPGD | |
| SCHEMBL10186210 | 0.77 | HPGD (0.44) | ALDH1A1KDM4EPOLBHPGDPKM | |
| SCHEMBL1721668 | 0.77 | ALDH1A1 (0.47) | ALDH1A1KDM4EPOLBHPGDPKM | |
| SCHEMBL7904292 | 0.77 | P2RX7 (0.47) | RAB9AALDH1A1KDM4EPOLBHPGD | |
| SCHEMBL1721772 | 0.76 | HDAC6 (0.43) | RAB9AALDH1A1KDM4EPOLBHPGD | |
| SCHEMBL7905582 | 0.74 | P2RX7 (0.43) | RAB9AALDH1A1KDM4EPOLBHPGD | |
| SCHEMBL10186512 | 0.74 | P2RX7 (0.41) | RAB9AALDH1A1KDM4EPOLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085134-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-20130085134-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-8357688-B2 | Substituted imidazo[1,5-a]quinoxalin-4(5H)-ones as PDE9 inhibitors | ASTELLAS PHARMA INC. (JP) | 2013-01-22 | — | — | US | disclosed |
| US-8357688-B2 | Substituted imidazo[1,5-a]quinoxalin-4(5H)-ones as PDE9 inhibitors | ASTELLAS PHARMA INC. (JP) | 2013-01-22 | — | — | US | disclosed |
| US-20110319385-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319385-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-12-29 | — | — | US | disclosed |
| WO-2010101230-A1 | QUINOXALINE COMPOUNDS | アステラス製薬株式会社 (JP) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085134-A1 | QUINOXALINE COMPOUND | PDE9A, PDE2A, PDE3A | RAB9A 32/4885ALDH1A1 387/4885KDM4E 1337/4885 |
| US-20110319385-A1 | QUINOXALINE COMPOUND | PDE9A, PDE5A, PDE3A | RAB9A 34/4885ALDH1A1 1344/4885KDM4E 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.